Upgrade to SI Premium - Free Trial

H.C. Wainwright cuts Sarepta (SRPT) price target to $0, reiterates Sell rating

July 21, 2025 6:42 AM
H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Sell rating on Sarepta Therapeutics (NASDAQ: SRPT) and lowered price target to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles